Pharmacology

Action Mechanism of Action Reference
BINDING AGENT Disialoganglioside GD2 binding agent FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neuroblastoma 4 D009447 ClinicalTrials
Osteosarcoma 2 D012516 ClinicalTrials
Small Cell Lung Carcinoma 2 D055752 ClinicalTrials
Ganglioneuroblastoma 2 D018305 ClinicalTrials

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
13.01
Nervous system disorders
12.6
Vascular disorders
10.0
Gastrointestinal disorders
8.77
Respiratory, thoracic and mediastinal disorders
7.4
Eye disorders
6.58
Cardiac disorders
5.75
Investigations
4.25
Infections and infestations
3.97
Renal and urinary disorders
3.97
Immune system disorders
3.42
Blood and lymphatic system disorders
3.29
Metabolism and nutrition disorders
3.29
Psychiatric disorders
3.15
Skin and subcutaneous tissue disorders
2.6
Hepatobiliary disorders
2.19
Musculoskeletal and connective tissue disorders
2.05

Cross References

Resources Reference
CAS NUMBER 1363687-32-4
ChEMBL CHEMBL3137342
FDA SRS 7SQY4ZUD30
Guide to Pharmacology 7979